To determine if daily rhythms in Mgmt promoter methylation impact diagnosis across the heterogeneity of GBM tumors, we next tested whether detecting Mgmt promoter methylation changes with time of collection in patient biopsies. The gene discussed is MGMT; the disease is glioblastoma.